ACI Worldwide Lifts Earnings Outlook Despite a 12% Drop in Quarterly Revenue

ACI Worldwide reported a 12% drop in Q3 revenue to $427M, citing delayed license renewals. Despite this, it raised its 2026 adjusted EBITDA forecast to $550M-$565M, expecting significant Q4 growth. License revenue fell 41%, while recurring revenue rose 4%. The company anticipates Q4 revenue of $612M-$642M, up 27%-33% YoY, and adjusted EBITDA of $257M-$272M, according to FinanceMagnates.com.

Original reporting
Published Nov 5, 2026, 11:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ACI Worldwide Lifts Earnings Outlook Despite a 12% Drop in Quarterly Revenue — source image
Decision brief

The 30-second read

$ACIBullishHigh
01

Why it matters

The EBITDA uplift may attract short‑term buying, but the 12% revenue drop keeps downside risk.

02

Market read

First‑report earnings guidance lift for a mid‑cap fintech firm; likely to move the stock on the day of release.

03

What to watch

Heavy reliance on Q4 earnings could expose ACI to a single-quarter downside if renewals shift again.

Relevance 8/10Novelty 8/10Timing: same day

Background

ACI Worldwide provides real‑time payments software to banks and processors; its earnings season often reflects license renewal timing.

Company-level read

Ticker impact

$ACIBullishHigh confidence
Context

ACI Worldwide lifted its 2026 adjusted EBITDA forecast to $550M-$565M and projects Q4 revenue of $612M-$642M after Q3 revenue fell 12% YoY.

Expected impact

potential upside as raised EBITDA guidance may boost investor sentiment.

Evidence & confidence

The new guidance concentrates earnings in the fourth quarter, reducing uncertainty and could drive the stock higher.

Market effects

Payments software sector may see renewed interest as ACI's guidance highlights seasonality.

North American fintech stocks could benefit from the positive earnings outlook.

Limited to firms with similar license‑renewal models; broader market effect modest.

Counterpoint

Revenue decline may signal deeper demand weakness, making the guidance raise risky.

Key entities

  • ACI Worldwide

    Payments software provider reporting Q3 results and 2026 guidance.

  • Thomas Warsop

    CEO of ACI Worldwide who commented on the guidance.

Related articles

$ACIMedAI 8/10

Albertsons ordered to pay $900 million in Washington opioid case

Albertsons Cos. was ordered to pay $900 million by a Washington state judge for contributing to the opioid epidemic. The ruling includes $800 million for opioid crisis efforts and $100 million in penalties. The judge found Albertsons failed to implement adequate safeguards and properly investigate suspicious prescriptions. Albertsons operated around 227 pharmacies in Washington at the time of the lawsuit.

$ACIHighAI 8/10

Albertsons ordered to pay $900M in Washington state opioid case

Albertsons must pay Washington state $900 million for its pharmacies' role in the opioid crisis, according to a state court ruling. The judge found Albertsons failed to prevent misuse of opioids. Albertsons plans to appeal and disagrees with the ruling. The company previously reached a $774 million framework to settle national opioid claims, contributing to a $500 million net loss in Q4 2025.

$ACIMed

ACI Worldwide, Inc. Q3 2026 Earnings Call Summary

ACI Worldwide reported a Q3 2026 revenue decline due to timing of license renewals. The company is transitioning to payments orchestration, with ACI Kinetic gaining its first live customer, Solaris, and signing a large African bank. Management is confident in meeting full-year targets, with 95% of revenue already secured. They expect meaningful revenue from Kinetic in 2027 and anticipate long-term growth driven by global payments complexity.

$ACIMedAI 8/10

Judge orders Albertsons to pay WA $900 million for role in opioid crisis

A judge ordered Albertsons to pay Washington $900 million for its role in the opioid crisis, citing the company's failure to prevent misuse. The funds will support treatment and prevention efforts. Albertsons plans to appeal, stating it disagrees with the ruling. The state alleges Albertsons pharmacies dispensed 641 million opioid pills with uninvestigated red flags between 2006 and 2022.